tousled1
12-15-2007, 02:43 PM
SAN ANTONIO, Dec. 14 -- Premenopausal breast cancer patients receiving adjuvant endocrine therapy did not suffer the substantial bone loss typically seen with such treatment when they were also given zoledronic acid (Zometa), updated results from a randomized clinical trial showed
To read full article: http://www.medpagetoday.com/MeetingCoverage/SABCSMeeting/tb/7690
To read full article: http://www.medpagetoday.com/MeetingCoverage/SABCSMeeting/tb/7690